Lv6
2620 积分 2024-12-16 加入
Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study
9天前
已完结
Cagrilintide–semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study
9天前
已关闭
Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
9天前
已完结
Unravelling the GIPR agonist versus antagonist paradox
21天前
已完结
The evolving landscape of obesity pharmacotherapy
1个月前
已完结
Asiaticoside attenuates renal fibrosis by targeting STAT3 to restore Th17/Treg homeostasis
1个月前
已完结
Asiaticoside protects against PDF-induced peritoneal fibrosis via suppression of AhR/Nrf2-mediated MMT and oxidative stress
1个月前
已完结
TMT quantitative proteomics and network pharmacology reveal the mechanism by which asiaticoside regulates the JAK2/STAT3 signaling pathway to inhibit peritoneal fibrosis
1个月前
已完结
A Phase 1, Randomised, Double-Blind, Placebo-Controlled Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN069 (a Dual GLP-1R Agonist and GIPR Antagonist) in Male Adults With Overweight or Obesity
1个月前
已完结
Calcitonin-induced change in serum calcium levels and its relationship to osteoclast morphology and number of calcitonin receptors
1个月前
已完结
皖公网安备34019202002308
